This is a comprehensive review of the published clinical studies related to pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). It includes clinical and hemodynamic definitions of the disease, epidemiology, pathophysiology, animal models and treatment approaches, and clinical trials. They importantly stress the urgent unmet need to make progress in this disease so as to reduce the high burden of the disease. This is a wonderful source document for finding the latest research and publications.
This is an in depth authoritative review of the field of pulmonary hypertension due to left heart disease. Written by one of the most renown thought leaders, it covers all facets of basic and clinical science, with insights into potential effective therapies. A must read for anyone who is involved with translational of clinical investigations in this area.
This editorial offers an explanation of the recent science that implicates downregulation of K+ATP channels in various forms of pulmonary hypertension. Given the clinical safety of levosimendan as a K+ATP channel activator, it may hold great promise for many forms of pulmonary hypertension.
This important review highlights the data showing a strong neurohormonal maladaptive basis underlying PH-HFpEF. These data provide a compelling argument for developing novel treatments that target these abnormalities to improve outcomes.
This is the first part of an extraordinary 2-part review of the complexity of pulmonary hypertension in LV dysfunction. One particularly enlightening focus is on the difference between the reversible elevations in pulmonary pressure vs. irreversible elevations which explain why persistent pulmonary hypertension occurs in many of these patients.
Comprehensive review of the pathophysiology of HFpEF by a worldwide leader in the field. This paper explains why the term diastolic dysfunction does not adequately explain the very complex and diverse pathophysiology that underlies the abnormal compliance of the LV in HFpEF.
This review covers the role of K+ATP channels in cardiovascular disease and links cellular metabolism to clinical disease states. This suggests that the exploitation of K+ATP channel activators may prove useful as a treatment for many facets of cardiovascular disease.
Current in-depth review of the clinical features and treatment approaches. A good reference source.
This important paper reviews 2 studies investigating the effects of splanchnic nerve block (SNB) on hemodynamics in patients with decompensated and ambulatory heart failure. They found that SNB reduced the estimated stressed blood volume in both studies at rest and throughout exercise. This provides strong validation of the role of stressed blood volume in PH-HFpEF.
Very high-level review of the role of K+ channels regulating the pulmonary vasculature. They explain how K+ channel conductance plays a fundamental role in pulmonary arterial function by controlling pulmonary vascular tone, regulating the population of PASMC through controlling cell apoptosis, survival, and proliferation, and by regulating the release of endothelial vasodilator factors. Given the demonstrated role of altered K+ channels in the pathophysiology of PH, drugs targeting K+ channels, could be new promising therapeutic agents in PAH.
© Copyright 2025 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design